Bellerophon therapeutics announces $5 million registered direct offering

Warren, n.j., march 06, 2023 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that it has entered into a subscription agreement with a life sciences-focused institutional investor to sell, in a registered direct offering, 718,474 shares of common stock at a price of $2.00 per share and 1,781,526 prefunded warrants at a price of $1.99 per pre-funded warrant for total gross proceeds of approximately $5 million, before deducting estimated offering expenses. the offering is expected to close on march 7, 2023, subject to the satisfaction of customary closing conditions.
BLPH Ratings Summary
BLPH Quant Ranking